Table III.
Treatment for Waldenstrom’s macroglobulinaemia with cutaneous involvement
| Group 1 | Group 2 | |
|---|---|---|
| No therapy, n (%) | 1 (8) | 0 |
| Treatment, n (%) | 11 (92) | 7 (100) |
| Median number of regimens, mean (range) | 1(0–3) | 2 (1–4) |
| First-line treatment, n (%) | n = 12 | n = 7 |
| Chlorambucil | 4 (33) | 0 |
| RCD | 2 (17) | 0 |
| CHOP +/– rituximab | 0 | 5 (71) |
| Ibrutinib | 1 (8) | 0 |
| Rituximab (mono-therapy) | 1 (8) | 0 |
| Bendamustine +/– rituximab | 3 (25) | 0 |
| GEMOX +/– rituximab | 0 | 1 (14) |
| Doxorubicin-cisplatin-cyclophosphamide | 0 | 1 (14) |
| Second-line treatments, n (%) | n = 5 | n = 5 |
| Chlorambucil | 1 (20) | 0 |
| RCD | 1 (20) | 0 |
| Ibrutinib | 1 (20) | 0 |
| Rituximab (mono-therapy) | 1 (20) | 0 |
| Bendamustine +/– rituximab | 1 (20) | 1 (20) |
| Fludarabin | 1 (20) | 0 |
| GEMOX +/– rituximab | 0 | 1 (20) |
| RICE | 0 | 2 (40) |
| RDHAC | 0 | 1 (20) |
| Radiotherapy | 1 (20) | 1 (20) |
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; GEMOX: gemcitabine, oxaliplatin; RCD: rituximab, cyclophosphamide, dexamethasone; RDHAC: rituximab, carboplatin, aracytine, dexamethasone; RICE: rituximab, ifosfamide, carboplatin, etoposide.